The RAS proteins undergo farnesylation of a carboxyl-terminal cysteine (the "C" of the carboxyl-terminal CaaX motif). Following farnesylation, the three amino acids downstream from the farnesylcysteine (the -aaX of the CaaX motif) are released by RAS converting enzyme 1 (RCE1). We previously showed that inactivation of Rce1 in mouse fibroblasts mislocalizes RAS proteins away from the plasma membrane and inhibits RAS transformation. We therefore hypothesized that inactivation of Rce1 might inhibit RAS transformation in vivo. To test this hypothesis, we used Cre/loxP recombination techniques to simultaneously inactivate Rce1 and activate a latent oncogenic K-RAS allele in hematopoietic cells in mice. Normally, activation of the oncogenic K-RAS allele in hematopoietic cells leads to a rapidly progressing and lethal myeloproliferative disease.
Introduction
Activating mutations in RAS genes result in constitutive signaling of the RAS proteins and are implicated in the pathogenesis of many human cancers, including several hematological malignancies 1, 2 . For example, activating mutations in RAS are present in up to 44% of patients with acute myeloid leukemia 3 . Hematological malignancies also occur when RAS signaling is increased, as observed in diseases such as neurofibromatosis (NF1) where there is a genetic abnormality in a RAS-interacting protein 4 .
The RAS proteins undergo several posttranslational processing steps, beginning with the farnesylation of the cysteine residue (the "C" of the CaaX motif) by protein farnesyltransferase (FTase). After this "lipidation" step, the last three amino acids of the protein (the -aaX of the CaaX motif) are released by RAS converting enzyme 1 (RCE1), and the newly exposed farnesylcysteine is methylated by isoprenylcysteine carboxyl methyltransferase (ICMT). Several RAS isoforms (but not K-RAS4B) are also palmitoylated at nearby cysteine residues 5 .
One strategy to block RAS-induced oncogenic transformation is to mistarget the RAS proteins within cells by inhibiting the enzymes that carry out the posttranslational modifications of the RAS proteins. Early preclinical trials of FTase inhibitors (FTIs) against RAS-induced tumors demonstrated significant efficacy with low toxicity 6 . However, in clinical trials of human solid tumors, the FTIs have not met the high expectations, in part because RAS proteins can be isoprenylated by a related isoprenyltransferase, geranylgeranyltransferase type I (GGTase-I), in the presence of an FTI 7 .
We have evaluated the possibility of inhibiting RCE1 as a strategy to prevent RAS-induced oncogenic transformation. One potential advantage of this strategy is that RCE1 inhibition would interfere with the processing of the RAS proteins regardless of whether they were farnesylated or geranylgeranylated. In addition, this strategy would not be expected to cause
For personal use only. on April 5, 2017 . by guest www.bloodjournal.org From significant toxicity in vivo. Indeed, we have inactivated Rce1 in the liver, spleen, and bone marrow of mice and not observed significant adverse effects 8 . Also, Ayiagari et al. 9 showed that Rce1-deficient fetal liver cells are capable of rescuing hematopoiesis in lethally irradiated mice.
Several lines of investigation suggest that inhibition of RCE1 would inhibit RAS-induced oncogenic transformation. First, inactivation of Rce1 mislocalized the RAS proteins and reduced cell proliferation and the anchorage-independent growth of RAS-transformed fibroblasts in soft agar and nude mice 8, 10 ; second, in the absence of Rce1, skin carcinoma cells grew slowly and were highly sensitive to the effects of an FTI 8 ; and third, several potent RCE1 inhibitors have been developed 11, 12 , and two of them reduced the anchorageindependent growth of K-RAS-transformed cells in vitro 13, 14 . However, nothing is known about the effects of inhibiting RCE1 on the growth of RAS-induced malignancies in vivo.
In this study, we determined if inactivation of Rce1 in mice would inhibit the development of a K-RAS-induced myeloproliferative disease (MPD) in vivo. To accomplish this, we used
Cre recombinase to simultaneously inactivate the expression of Rce1 and activate the expression of oncogenic K-RAS G12D in hematopoietic cells.
Materials and Methods

Breeding mice for in vivo experiments
Mice with a conditional Rce1 knockout allele (Rce1 fl ) have been described 8 
Injection of polyinosinic-polycytidylic acid and monitoring
The Mx1-Cre transgene was activated with intraperitoneal injections of 400 µg polyinosinicpolycytidylic acid (pI-pC; Sigma) 21 days after birth (at weaning) once every other day for a total of four injections. Blood was drawn from a tail vein before the first pI-pC injection weeks, groups of mice were sacrificed and tissues harvested.
Histology
Tissues were fixed in 4% PBS-buffered formalin, dehydrated in 70-100% ethanol, and cleared in xylene. The tissues were embedded in paraffin and 4-5 µm sections were stained with hematoxylin and eosin. Sections were viewed and photographed in a Zeiss Axioplan 2 light microscope. Cytospin preparations of bone marrow cells were stained with MayGrünwald-Giemsa. Cells of the monocytic and granulocytic lineages were identified by staining for nonspecific and specific esterases, respectively, using α-naphthyl butyrate and naphtol AS-D chloroacetate as substrates.
Colony assays
Spleen cells (10 5 ) and bone marrow cells (2 × 10 4 ) harvested 5 weeks after pI-pC injections of 
Statistical analyses
Data are plotted as mean and standard error of the mean (SEM). Differences in the concentrations and percentages of white blood cells, the colony-forming ability of hematopoietic cells, and the proliferation of cells in culture were determined with Student's t test; survival was assessed by the Mann-Whitney U test.
For (Figure 2A and supplementary table) . Overall, 58% of white blood cells in these mice were immature. There was a proportionate reduction in the percentage of lymphocytes in the two groups of mice ( Figure 2B) . Thus, the increase in white blood cell counts in pI-pC-treated Rce1 fl/fl K LSL M mice relative to control mice with MPD was due to an accumulation of immature myeloid cells.
Results
Inactivation of Rce1 exacerbates K-RAS-induced myeloproliferative disease
To determine if
To determine if the enhanced production of immature white blood cells was associated with increased myeloid infiltration into vital tissues, we carried out histological studies. Five To determine the efficiency of Cre-induced recombination in hematopoietic tissues of pI-pCinjected Rce1 fl/fl K LSL M, we performed quantitative PCR of genomic DNA: the efficiency was 95 ± 1.6% in spleen and 90 ± 2.2% in bone marrow (n = 3). Thus, the majority of the cells in those tissues had inactivated both alleles of Rce1.
To determine the consequences of inactivating Rce1 in K-RAS G12D -expressing tissues on downstream signaling molecules, we performed western blots. There were increased levels of phosphorylated ERK1/2 in the spleens and livers of pI-pC-injected Rce1 fl/+ K LSL M and 
Rce1 deficiency does not enhance the proliferation of K-RAS G12D -expressing fibroblasts
To determine the impact of Rce1 deficiency on the proliferation of other cell types expressing 
Discussion
We suspected that inactivation of Rce1 would inhibit the development of a K-RAS-induced MPD in vivo. This suspicion was not upheld. To our surprise, the inactivation of Rce1 accelerated the development of MPD, increased the release of immature and dysplastic cells into the circulation, and caused mice to die more rapidly, probably because of infiltration and proliferation of cells in vital tissues. These studies suggest that RCE1 inhibitors would not be useful for the treatment of RAS-induced hematological malignancies. Indeed, such a strategy could be harmful.
Our experiments involved the use of Cre recombinase to simultaneously inactivate Rce1 and activate K-RAS G12D . This strategy worked as planned. PCR analyses of genomic DNA from multiple individual splenocyte colonies confirmed that Rce1 had been fully deleted and that the Kras2 G12D allele was activated. Moreover, Rce1 was deleted in more than 90% of the cells in spleen and bone marrow as judged by quantitative PCR.
Activation of the K-RAS G12D allele led to a rapidly progressing MPD, with splenomegaly, increased numbers of mature granulocytes in the circulation, and infiltration of cells in liver and spleen. However, fewer than 20% of the myeloid cells in the blood were immature, so we cannot claim that the mice developed an acute leukemia syndrome. These findings are entirely consistent with earlier studies on the activation of the latent K-RAS G12D allele in hematopoietic cells by Braun et al. 17 and Chan et al. 18, 19 . In the setting of Rce1 deficiency, the K-RAS G12D -induced MPD progressed into an accelerated-phase MPD with a maturation arrest evident by the more severe leukocytosis and the dramatic increase in the number of immature myeloid cells in the blood. Also, Rce1-deficient hematopoietic cells displayed an
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The finding of increased numbers of white blood cells in the absence of Rce1 expression is consistent with data reported a few years ago by Aiyagari and coworkers 9 . To define the functional importance of Rce1 in normal hematopoiesis, they compared the ability of Rce1 -/-and wild-type fetal liver cells to rescue hematopoiesis in lethally irradiated mice. The mice that were replenished with Rce1 -/-cells actually had higher white blood cell counts than mice receiving Rce1 +/-or Rce1 +/+ cells. At the time, it was unclear whether the higher white blood cell counts were truly significant or simply due to a play of chance. In light of the current studies, we suggest that the increased white blood cell counts were in fact due to Rce1 deficiency, and we further suggest that Rce1 deficiency accelerates the proliferation of both normal and K-RAS G12D -expressing hematopoietic cells.
We showed previously that inactivation of Rce1 mislocalizes the RAS proteins away from the plasma membrane and reduces the proliferation of skin carcinoma cells, wild-type fibroblasts, and fibroblasts that overexpress a mutationally activated form of RAS (driven by a strong viral promoter) 8 . Our current studies reinforced those data: Rce1 deficiency reduced the proliferation of fibroblasts in which the latent K-RAS G12D allele was activated (with K-RAS expression driven by the endogenous Kras2 promoter). Thus, our studies indicate that Rce1 deficiency has distinct effects in fibroblasts and hematopoietic cells.
At this point, the mechanism for the worsened MPD and the increased proliferation of Rce1-deficient hematopoietic cells is unknown. The simplest potential explanation would be that RCE1 normally processes an isoprenylated CaaX protein that suppresses cell proliferation and that this protein is dysfunctional in the absence of RCE1-mediated endoproteolytic processing. One potential candidate is RAP1, a RCE1 substrate which is known to be 
